On April 29th, Xingqi Pharmaceutical surged 14.14%. The company's quarterly report shows that in the first quarter of this year, the Kuwait Investment Authority and the well-known fund manager of China Europe Fund, Ge Lan, significantly increased their positions, both newly entering the top ten circulating shareholders of Xingqi Pharmaceutical. From the stock price trend of Xingqi Pharmaceutical, since June of last year, the stock price has experienced severe adjustments. According to Xingqi Pharmaceutical's Q1 2025 report, as of the end of the first quarter of this year, the Kuwait Investment Authority became a new entrant among the top ten circulating shareholders of Xingqi Pharmaceutical, holding 2.9353 million shares; the China Europe Medical Health Mixed Fund managed by Ge Lan held 939,000 shares, also newly entering the top ten circulating shareholders